| abstract |
The present invention provides the application of MDSCs as biomarkers in identifying congenital aplastic anemia and acquired aplastic anemia. The inventors have found for the first time that there are significant differences in the content of MDSCs in peripheral blood of patients with congenital aplastic anemia and acquired aplastic anemia, indicating that MDSCs can be used as specific biomarkers to identify congenital aplastic anemia and acquired aplastic anemia. Aplastic anemia, therefore, the reagent for detecting the content of MDSCs in the peripheral blood of the subject can be used as a reagent for distinguishing CAA and AAA. MDSCs can easily, quickly and efficiently identify congenital aplastic anemia and acquired aplastic anemia, so as to avoid delaying the treatment of patients due to misdiagnosis. It has the advantages of non-invasiveness, strong practicability and easy promotion. |